FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783990347> ?p ?o ?g. }

• W2783990347 endingPage "21" @default.
• W2783990347 startingPage "11" @default.
• W2783990347 abstract "Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection Bhagyashri D Navalkele,1 Teena Chopra2 1Internal Medicine and Infectious Diseases, University of Mississippi Medical Center, Jackson, MS, USA; 2Internal Medicine and Infectious Diseases, Infection Prevention and Epidemiology, Detroit Medical Center, Wayne State University, Detroit, MI, USA Abstract: Clostridium difficile infection (CDI) is the most common health care-acquired infection associated with high hospital expenditures. The incidence of subsequent recurrent CDI increases with prior episodes of CDI, 15%–35% risk after primary CDI to 35%–65% risk after the first recurrent episode. Recurrent CDI is one of the most challenging and a very difficult to treat infections. Standard guidelines provide recommendations on treatment of primary CDI. However, treatment choices for recurrent CDI are limited. Recent research studies have focused on the discovery of newer alternatives for prevention of recurrent CDI targeting prime virulence factors involved in C. difficile pathogenesis. Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Multiple in vitro and in vivo animal studies have demonstrated direct binding of bezlotoxumab to C. difficile toxin B preventing intestinal epithelial damage and colitis. Furthermore, this monoclonal antibody mediates early reconstitution of gut microbiota preventing risk of recurrent CDI. Randomized placebo-controlled trials showed concomitant administration of a single intravenous dose of 10 mg/kg of bezlotoxumab, in patients on standard-of-care therapy for CDI, had no substantial effect on clinical cure rates but significantly reduced the incidence of recurrent CDI (~40%). It shows efficacy against multiple strains, including the epidemic BI/NAP1/027 strain. Bezlotoxumab is a US Food and Drug administration-approved, safe and well-tolerated drug with low risk of serious adverse events and drug–drug interactions. Bezlotoxumab has emerged as a novel dynamic adjunctive therapy for prevention of recurrent CDI. Further studies on real-world experience with bezlotoxumab and its impact in reducing rates of recurrent CDI are needed. Keywords: bezlotoxumab, Clostridium difficile, monoclonal antibody, novel CDI treatment, anti-toxin B antibody, prevention of recurrent CDI" @default.
• W2783990347 created "2018-01-26" @default.
• W2783990347 creator A5077066823 @default.
• W2783990347 creator A5078242346 @default.
• W2783990347 date "2018-01-01" @default.
• W2783990347 modified "2023-09-30" @default.
• W2783990347 title "Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent <em>Clostridium difficile </em>infection" @default.
• W2783990347 cites W1916481354 @default.
• W2783990347 cites W1996646253 @default.
• W2783990347 cites W2001769662 @default.
• W2783990347 cites W2007264670 @default.
• W2783990347 cites W2012852554 @default.
• W2783990347 cites W2018793707 @default.
• W2783990347 cites W2025024815 @default.
• W2783990347 cites W2049511418 @default.
• W2783990347 cites W2071054182 @default.
• W2783990347 cites W2071874661 @default.
• W2783990347 cites W2101233913 @default.
• W2783990347 cites W2104815174 @default.
• W2783990347 cites W2108975442 @default.
• W2783990347 cites W2130111166 @default.
• W2783990347 cites W2131038214 @default.
• W2783990347 cites W2144370711 @default.
• W2783990347 cites W2152417583 @default.
• W2783990347 cites W2153155854 @default.
• W2783990347 cites W2166660180 @default.
• W2783990347 cites W2202785594 @default.
• W2783990347 cites W2208337377 @default.
• W2783990347 cites W2273363457 @default.
• W2783990347 cites W2333302180 @default.
• W2783990347 cites W2346636740 @default.
• W2783990347 cites W2431375768 @default.
• W2783990347 cites W2470029570 @default.
• W2783990347 cites W2516010400 @default.
• W2783990347 cites W2528556191 @default.
• W2783990347 cites W2529382623 @default.
• W2783990347 cites W2558028312 @default.
• W2783990347 cites W2582069104 @default.
• W2783990347 cites W2611907043 @default.
• W2783990347 cites W4246794056 @default.
• W2783990347 doi "https://doi.org/10.2147/btt.s127099" @default.
• W2783990347 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5779312" @default.
• W2783990347 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29403263" @default.
• W2783990347 hasPublicationYear "2018" @default.
• W2783990347 type Work @default.
• W2783990347 sameAs 2783990347 @default.
• W2783990347 citedByCount "33" @default.
• W2783990347 countsByYear W27839903472018 @default.
• W2783990347 countsByYear W27839903472019 @default.
• W2783990347 countsByYear W27839903472020 @default.
• W2783990347 countsByYear W27839903472021 @default.
• W2783990347 countsByYear W27839903472022 @default.
• W2783990347 countsByYear W27839903472023 @default.
• W2783990347 crossrefType "journal-article" @default.
• W2783990347 hasAuthorship W2783990347A5077066823 @default.
• W2783990347 hasAuthorship W2783990347A5078242346 @default.
• W2783990347 hasBestOaLocation W27839903471 @default.
• W2783990347 hasConcept C120665830 @default.
• W2783990347 hasConcept C121332964 @default.
• W2783990347 hasConcept C126322002 @default.
• W2783990347 hasConcept C134193097 @default.
• W2783990347 hasConcept C159654299 @default.
• W2783990347 hasConcept C203014093 @default.
• W2783990347 hasConcept C2909592510 @default.
• W2783990347 hasConcept C2994496256 @default.
• W2783990347 hasConcept C501593827 @default.
• W2783990347 hasConcept C542903549 @default.
• W2783990347 hasConcept C61511704 @default.
• W2783990347 hasConcept C71924100 @default.
• W2783990347 hasConcept C86803240 @default.
• W2783990347 hasConcept C89423630 @default.
• W2783990347 hasConcept C97505648 @default.
• W2783990347 hasConceptScore W2783990347C120665830 @default.
• W2783990347 hasConceptScore W2783990347C121332964 @default.
• W2783990347 hasConceptScore W2783990347C126322002 @default.
• W2783990347 hasConceptScore W2783990347C134193097 @default.
• W2783990347 hasConceptScore W2783990347C159654299 @default.
• W2783990347 hasConceptScore W2783990347C203014093 @default.
• W2783990347 hasConceptScore W2783990347C2909592510 @default.
• W2783990347 hasConceptScore W2783990347C2994496256 @default.
• W2783990347 hasConceptScore W2783990347C501593827 @default.
• W2783990347 hasConceptScore W2783990347C542903549 @default.
• W2783990347 hasConceptScore W2783990347C61511704 @default.
• W2783990347 hasConceptScore W2783990347C71924100 @default.
• W2783990347 hasConceptScore W2783990347C86803240 @default.
• W2783990347 hasConceptScore W2783990347C89423630 @default.
• W2783990347 hasConceptScore W2783990347C97505648 @default.
• W2783990347 hasLocation W27839903471 @default.
• W2783990347 hasLocation W27839903472 @default.
• W2783990347 hasLocation W27839903473 @default.
• W2783990347 hasLocation W27839903474 @default.
• W2783990347 hasOpenAccess W2783990347 @default.
• W2783990347 hasPrimaryLocation W27839903471 @default.
• W2783990347 hasRelatedWork W187507872 @default.
• W2783990347 hasRelatedWork W2025842490 @default.
• W2783990347 hasRelatedWork W2043555715 @default.
• W2783990347 hasRelatedWork W2075464527 @default.
• W2783990347 hasRelatedWork W2077395702 @default.

• next